Skip to content
- Breaking News
Real-World Experience of Pazopanib and Sorafenib in Patients with Desmoid Tumors: A CanSaRCC Multi-Center Study - Breaking News

We are excited to share groundbreaking research co-authored by Dr. Jonathan Noujaim and Dr. Ramy Saleh, co-founders of SaRC-Q, that delves into the real-world application of tyrosine kinase inhibitors (TKIs) sorafenib and pazopanib in treating desmoid tumors (DT). This retrospective study, the largest of its kind, offers significant insights into long-term patient outcomes and the efficacy of these treatments.

Study Overview: The study reviewed data from 142 patients diagnosed with DTs and treated with either sorafenib or pazopanib between 2011 and 2022 across 11 institutions. Patient histories, responses to therapy, and toxicities were meticulously recorded and analyzed using Kaplan-Meier and log-rank tests. This retrospective study represents the largest cohort of DT patients treated with sorafenib or pazopanib to date.

Key Findings:

  • Disease Control: The overall disease control rate was an impressive 95.1%, with a 26.0% overall response rate.
  • Tumor Response: Median tumor shrinkage was -8.5%, ranging from complete reduction to slight increases in size.
  • Survival Rates: The 1-year and 2-year progression-free survival rates were 82% and 80%, respectively.
  • Treatment Duration and Adverse Events: The median treatment duration was 10.8 months. Dose reductions were necessary for 23.9% of patients, and 25.4% experienced Grade 3 or higher adverse events.
  • Treatment Discontinuation: 59.9% of patients discontinued treatment, primarily due to toxicity or disease progression. Importantly, discontinuation in responders was found to be safe.

Conclusions: This study underscores the potential of sorafenib and pazopanib in managing desmoid tumors effectively. It also highlights the need for further research to determine the optimal treatment duration, especially for patients with stable disease.

Dr. Noujaim and Dr. Saleh’s contribution to this research marks a significant milestone in DT treatment, providing hope and direction for future therapies.

For those interested in exploring the full details of this study, please visit the article on ScienceDirect: Real-World Experience of Pazopanib and Sorafenib in Patients with Desmoid Tumors.

Stay tuned to SaRC-Q for more updates on our ongoing efforts to advance cancer research and improve patient outcomes.